Profile data is unavailable for this security.
About the company
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
- Revenue in USD (TTM)6.26bn
- Net income in USD1.50bn
- Incorporated2012
- Employees10.60k
- LocationZoetis Inc10 Sylvan WayPARSIPPANY 07054-3825United StatesUSA
- Phone+1 (973) 822-7000
- Fax+1 (302) 655-5049
- Websitehttps://www.zoetis.com/
Mergers & acquisitions
| Acquired company | ZTS:NYQ since announced | Transaction value |
|---|---|---|
| ZNLabs LLC | 15.11% | -- |
| Phoenix Central Laboratory For Veterinarians Inc | 8.46% | -- |
| Platinum Performance Inc | 21.30% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | 7.86bn | 2.12bn | 46.80bn | 8.10k | 23.03 | 4.23 | 20.12 | 5.95 | 18.47 | 18.47 | 68.59 | 100.56 | 0.5926 | 0.8517 | 3.20 | 970,790.10 | 15.94 | 17.80 | 18.40 | 20.74 | 90.05 | 92.16 | 26.91 | 25.67 | 3.18 | 77.00 | 0.0605 | 0.00 | 17.18 | 22.77 | -10.97 | 44.30 | 5.23 | -- |
| Vertex Pharmaceuticals Incorporated | 4.16bn | 1.18bn | 61.45bn | 3.00k | 52.58 | 10.09 | 47.87 | 14.76 | 4.51 | 4.51 | 15.97 | 23.50 | 0.5716 | 3.75 | 7.98 | 1,387,607.00 | 16.16 | 5.48 | 19.44 | 6.99 | 86.84 | 87.50 | 28.27 | 9.03 | 3.49 | -- | 0.0855 | 0.00 | 36.59 | 48.30 | 119.39 | -- | 8.06 | -- |
| Allergan plc | 16.09bn | -5.27bn | 65.20bn | 17.40k | -- | 1.12 | 81.91 | 4.05 | -15.98 | -15.98 | 48.91 | 177.03 | 0.1638 | 2.51 | 5.31 | 924,649.40 | -5.36 | -3.72 | -5.86 | -4.00 | 84.56 | 84.81 | -32.73 | -27.65 | 0.9027 | 0.0146 | 0.2802 | -- | 1.91 | 28.03 | -2.21 | -- | 9.55 | -- |
| Zoetis Inc | 6.26bn | 1.50bn | 65.73bn | 10.60k | 44.29 | 24.30 | 34.38 | 10.50 | 3.12 | 3.12 | 13.04 | 5.69 | 0.5609 | 1.41 | 5.90 | 590,566.10 | 13.44 | 11.62 | 15.55 | 13.71 | 68.43 | 66.83 | 23.96 | 18.90 | 1.85 | 10.07 | 0.7042 | 22.90 | 7.47 | 5.52 | 8.46 | 20.80 | 20.64 | 17.02 |
| Gilead Sciences, Inc. | 22.45bn | 5.39bn | 92.23bn | 11.00k | 17.32 | 4.07 | 24.73 | 4.11 | 4.21 | 4.21 | 17.61 | 17.89 | 0.3583 | 3.25 | 6.50 | -- | 8.56 | 18.07 | 10.24 | 21.88 | 79.18 | 83.42 | 23.89 | 39.31 | 3.01 | 5.60 | -- | 24.87 | 1.46 | -2.04 | -1.34 | -14.95 | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2019 | 36.57m | 7.68% |
| BlackRock Fund Advisorsas of 31 Dec 2019 | 23.95m | 5.03% |
| SSgA Funds Management, Inc.as of 31 Dec 2019 | 19.88m | 4.18% |
| State Farm Investment Management Corp.as of 31 Dec 2019 | 18.13m | 3.81% |
| AllianceBernstein LPas of 31 Dec 2019 | 13.95m | 2.93% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2019 | 11.11m | 2.33% |
| Polen Capital Management LLCas of 31 Dec 2019 | 10.83m | 2.27% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2019 | 9.61m | 2.02% |
| ClearBridge Investments LLCas of 31 Dec 2019 | 9.16m | 1.92% |
| Massachusetts Financial Services Co.as of 31 Dec 2019 | 7.96m | 1.67% |
